SOPHiA GENETICS SA(SOPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SOPH SOPHiA GENETICS SA

Post-Mkt 04-24 19:26:07 EDT

3.05

-0.01

-0.33%

盘后3.14

+0.09+2.95%

18:50 EDT

High3.11	Low3.03	Vol6.52K
Open3.04	D1 Closing3.06	Amplitude2.61%
Mkt Cap203.83M	Tradable Cap158.94M	Total Shares66.83M
T/O19.97K	T/O Rate0.01%	Tradable Shares52.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SOPH","market":"US","secType":"STK","nameCN":"SOPHiA GENETICS SA","latestPrice":3.05,"timestamp":1745524800000,"preClose":3.06,"halted":0,"volume":6519,"hourTrading":{"tag":"盘后","latestPrice":3.14,"preClose":3.05,"latestTime":"18:50 EDT","volume":348,"amount":1063.2199355999999,"timestamp":1745535028367},"delay":0,"floatShares":52110498,"shares":66831071,"eps":-0.945972,"marketStatus":"Post-Mkt","change":-0.01,"latestTime":"04-24 19:26:05 EDT","open":3.04,"high":3.11,"low":3.03,"amount":19965.128514,"amplitude":0.026144,"askPrice":3.96,"askSize":100,"bidPrice":2.98,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-0.945972,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745539200000},"marketStatusCode":4,"adr":0,"listingDate":1627012800000,"exchange":"NASDAQ","adjPreClose":3.06,"preHourTrading":{"tag":"盘前","latestPrice":3.12,"preClose":3.06,"latestTime":"07:55 EDT","volume":24,"amount":74.88,"timestamp":1745495708571},"postHourTrading":{"tag":"盘后","latestPrice":3.14,"preClose":3.05,"latestTime":"18:50 EDT","volume":348,"amount":1063.2199355999999,"timestamp":1745535028367},"volumeRatio":0.276182,"impliedVol":1.1272,"impliedVolPercentile":0.424},"requestUrl":"/m/hq/s/SOPH/wiki","defaultTab":"wiki","newsList":[{"id":"2530962679","title":"Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2530962679","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530962679?lang=en_us&edition=full_marsco","pubTime":"2025-04-25 03:00","pubTimestamp":1745521200,"startTime":"0","endTime":"0","summary":"Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI’s de-identified oncology data. This partnership is a big win, matching Tempus AI’s fourth-quarter 2024 revenues alone.But with the stock on fire, the big question is, will the rally continue, or is Tempus AI already priced for perfection?TEM-AZN-Pathos AI Deal to Build Foundation for Long-term Stability. This partnership not only highlights the value of TEM’s AI and data assets but also deepens its existing relationship with AstraZeneca. With the deal value alone matching Tempus AI’s fourth-quarter 2024 revenues, it’s a major milestone that could lead to more licensing opportunities and position Tempus as a key player in AI-driven precision medicine.Not only this, the launch of the xT CDx in vitro diagnostic device and the Olivia health conci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-ai-stock-sees-21-190000403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1043141123.HKD","LU1116320737.USD","LU2087621335.USD","LU0130517989.USD","LU0690374615.EUR","LU0868494617.USD","LU2236285917.USD","GB00B4QBRK32.GBP","LU1951198990.SGD","LU0130518102.USD","LU0203347892.USD","LU2168564065.EUR","BK4598","LU2087625088.SGD","LU2242649171.HKD","LU1951200564.SGD","LU2592432038.USD","LU2491050071.SGD","LU1699723380.USD","LU2097344357.USD","LU0345769631.USD","LU0820562030.AUD","LU1935043536.SGD","LU2168564495.EUR","LU2360032135.SGD","LU2471134796.USD","SOPH","IE00BKPKM429.USD","LU1778281490.HKD","LU0354030438.USD","IE00BMPRXN33.USD","LU2362541273.HKD","AZN","LU1066051811.HKD","LU2125154778.USD","BK4077","IRTC","LU0823434583.USD","LU1670627923.USD","LU1032955483.USD","LU2505996681.GBP","SG9999015945.SGD","SGXZ99366536.SGD","IE00BMPRXR70.SGD","LU2456880835.USD","LU0708994859.HKD","LU0353189680.USD","TEM","LU0942090050.USD"],"gpt_icon":1},{"id":"2529304958","title":"SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529304958","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529304958?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 20:00","pubTimestamp":1745323200,"startTime":"0","endTime":"0","summary":"BOSTON andROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS , a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.  EDT / 2:00 p.m.  CET.The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/sophia-genetics-announce-financial-results-120000721.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sophia-genetics-announce-financial-results-120000721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","SOPH","BK4167"],"gpt_icon":0},{"id":"2525855479","title":"SOPHiA GENETICS Partners With Precision for Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2525855479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525855479?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 15:58","pubTimestamp":1744099082,"startTime":"0","endTime":"0","summary":"SOPHiA GENETICS  partnered with Precision for Medicine to enhance biomarker discovery and precision medicine services, Precision for Medicine said Tuesday.The company said it will integrate SOPHiA's DDM Platform for biomarker discovery, clinical trial assays, and advanced algorithms to expand its clinical trial capabilities.The partnership will enable biopharma companies to accelerate clinical trial design, patient stratification, and data analysis through AI-driven algorithms that analyze complex multimodal data, including genomic, radiomic, and clinical data, the company said.Additionally, the company said the MSK-ACCESS liquid biopsy test powered by SOPHiA DDM, supported by AstraZeneca , will be available as a service for biopharma clients.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AZN","LU0320765992.SGD","BK4568","BK4585","SOPH","LU1829250122.USD","LU2417539215.USD","LU2456880835.USD","BK4539","BK4588","LU0889565916.HKD","LU2236285917.USD","LU2462157665.USD","LU0109394709.USD","BK4007","BK4167"],"gpt_icon":0},{"id":"2525831256","title":"Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2525831256","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525831256?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 14:00","pubTimestamp":1744092000,"startTime":"0","endTime":"0","summary":"The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster.BETHESDA, Md. and BOSTON and ROLLE, Switzerland, April 8, 2025 /PRNewswire/ -- Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and precision medicine services. As part of this collaboration, Precision for Medicine will integrate the SOPHiA DDM Platform for biomarker discovery, clinical trial assays , and advanced algorithms to expand clinical trial capabilities. This partnership will further enhance service offerings and provide biopharma companies with tools to accelerate clinical trial design, patient stratification, and data analysis.Through this partnership, Precision for Medicine will provide wet lab services,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/precision-medicine-partners-sophia-genetics-060000649.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/precision-medicine-partners-sophia-genetics-060000649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","SOPH","BK4539"],"gpt_icon":0},{"id":"2524732094","title":"RBC Capital Remains a Buy on SOPHiA GENETICS (SOPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524732094","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524732094?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 09:47","pubTimestamp":1743644835,"startTime":"0","endTime":"0","summary":"In a report released on April 1, Conor McNamara from RBC Capital maintained a Buy rating on SOPHiA GENETICS (SOPH – Research Report), with a price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-sophia-genetics-soph-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-sophia-genetics-soph-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","BK4539","SOPH","BK4207"],"gpt_icon":0},{"id":"2524129431","title":"Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524129431","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524129431?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 03:00","pubTimestamp":1743534000,"startTime":"0","endTime":"0","summary":"The healthcare technology space is gaining enormous investors' attention these days, thanks to the rapid advancements in artificial intelligence  in this niche. Companies like Tempus AI TEM are leading the charge by leveraging AI for precision medicine. The stock’s 42.9% surge year to date strongly underscores a broader market shift—highlighting the increasing belief that AI-driven healthcare is gaining strength as a high-value investment opportunity.Year to date, the stock has outperformed the 6.6% growth of the Medical Info Systems industry and the Medical sector’s 3.1% increase. In the meantime, the benchmark S&P 500 has declined 5.3%. The company has also outperformed other players in the health infotech field like iRhythm Technologies IRTC and SOPHiA GENETICS SOPH, which have improved 16.1% and 8.1%, respectively, during the same period.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-ai-surges-43-ytd-190000725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0348723411.USD","LU0158827781.USD","LU0823421416.USD","LU2097344357.USD","LU0130517989.USD","LU1059921491.USD","LU0494093205.USD","LU2265009873.SGD","LU1988902786.USD","LU1880398471.USD","LU0225283273.USD","EPS","LU1839511570.USD","LU1366192091.USD","IE0034235303.USD","LU2417539215.USD","LU2500361329.USD","LU0345774391.USD","LU0061474705.USD","LU0477156953.USD","CMS","TEM","LU0964807845.USD","LU0006306889.USD","IE00B1XK9C88.USD","SOPH","SG9999015945.SGD","LU0128525689.USD","LU0310800379.SGD","LU0792757196.USD","IE00BZ1G4Q59.USD","LU0077335932.USD","LU1951200564.SGD","LU0215105999.USD","IRTC","LU1066051498.USD","LU2077746001.SGD","LU2592432038.USD","SG9999014880.SGD","LU1868837300.USD","BK4613","LU2191332357.HKD","BK4563","LU0170899867.USD","LU2125154778.USD","LU0080751232.USD","BK4602","LU2362541513.USD","LU0130102774.USD"],"gpt_icon":1},{"id":"2521631253","title":"SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521631253","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521631253?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 00:00","pubTimestamp":1742572809,"startTime":"0","endTime":"0","summary":"SOPHiA GENETICS SA  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.As such, the Zacks rating upgrade for SOPHiA GENETICS is essentially a positive comment on its earnings outlook that could have a favor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sophia-genetics-soph-upgraded-buy-160009473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SOPH"],"gpt_icon":0},{"id":"2520560520","title":"SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC","url":"https://stock-news.laohu8.com/highlight/detail?id=2520560520","media":"CNW Group","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520560520?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 21:00","pubTimestamp":1742302800,"startTime":"0","endTime":"0","summary":"BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /CNW/ -- SOPHiA GENETICS , a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data.\"When we announced one million profiles analyzed in 2022, it was a landmark moment in the evolution of data-driven medicine,\" said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder of SOPHiA GENETICS. \"Less than three years later, we have doubled that number, an acceleration that reflects both the trust our partners place in our Platform and the increasing role of AI in transforming healthcare.\". \"At SOPHiA GENETICS, our vision was to create a Platform that could harness genetic data to benef","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sophia-genetics-announces-two-million-130000823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVDU","LU1084165304.USD","LU2491049909.HKD","NVDD","LU2413666426.HKD","IE0004445239.USD","LU0965509010.AUD","LU1242518857.USD","NVD2.UK","LU2097344431.USD","SOPH","BK4585","LU2361044949.HKD","LU2750360641.GBP","NVDY","LU1791710400.SGD","LU1868837136.USD","LU0476273544.USD","LU1839511570.USD","HK0000320223.HKD","SNVD.UK","LU2125154935.USD","LU0823434583.USD","LU2242649171.HKD","NVD3.UK","IE00BFSS7M15.SGD","NVDS","IE00BD6J9T35.USD","2NVD.UK","3NVD.UK","LU2360106780.USD","LU2750360997.AUD","LU0964807845.USD","IE00B19Z8W00.USD","NVIW.SI","LU0072462426.USD","LU2106854487.HKD","LU0472753341.HKD","NVDS.UK","LU2403377893.USD","LU1721428933.USD","LU0417517546.SGD","LU1629891620.HKD","LU1551013425.SGD","LU0820561909.HKD","LU1804176565.USD","NVD"],"gpt_icon":1},{"id":"2520497649","title":"SOPHiA GENETICS (SOPH) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2520497649","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520497649?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 17:58","pubTimestamp":1742291913,"startTime":"0","endTime":"0","summary":"BTIG analyst Mark Massaro reiterated a Buy rating on SOPHiA GENETICS (SOPH – Research Report) yesterday and set a price target of $5.00. The compan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sophia-genetics-soph-gets-a-buy-from-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sophia-genetics-soph-gets-a-buy-from-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SOPH","BK4539","BK4167"],"gpt_icon":0},{"id":"2520099895","title":"Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520099895","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520099895?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 00:22","pubTimestamp":1742228520,"startTime":"0","endTime":"0","summary":"Artificial Intelligence -based healthcare solutions company Tempus AI TEM has continued to capture investors’ attention despite reporting weaker-than-expected fourth-quarter 2024 results on Feb. 24, 2025. The earnings miss led to an immediate decline in the company’s share price, raising short-term concerns among investors. However, analysts continue to express confidence in Tempus AI’s long-term growth trajectory, backed by strategic acquisitions, partnerships, and expanding revenue streams. In particular, its latest acquisition of Deep 6 AI  is expected to enhance its capabilities in clinical trial matching, potentially driving future growth and leading to a rebound in stock performance.Following the announcement of the Deep 6 AI acquisition on March 11, shares of the company have gained 3.5%.Year to date, the stock has rallied 39.7%, outperforming the 8.6% growth of the Medical Info Systems industry and the Medical sector’s 3.8% increase. In the meantime, the benchmark S&P 500 has d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-ai-surges-40-ytd-162200901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SOPH","LU0354030511.USD","LU0648000940.SGD","TEM","LU1642822529.SGD","IE00BJTD4V19.USD","BK4543","LU1316542783.SGD","SGXZ81514606.USD","LU0154236417.USD","LU1366333091.USD","LU2092937148.SGD","BK4534","LU0354030438.USD","LU2087625088.SGD","LU0061475181.USD","LU0994945656.USD","SG9999015986.USD","IE00BK4W5M84.HKD","LU1935043023.USD","IE00BK4W5L77.USD","BK4532","LU2756315664.SGD","LU0109391861.USD","LU0345774391.USD","LU0823434583.USD","CMS","LU1670628061.USD","IRTC","LU0792757196.USD","LU1868836914.USD","BK4527","LU2242650005.HKD","LU1201861165.SGD","LU1267930730.SGD","LU0943347566.SGD","LU1935042488.USD","SG9999014898.SGD","LU0225283273.USD","LU2505996509.AUD","LU1989764664.SGD","LU0215105999.USD","LU0320765059.SGD","SG9999015952.SGD","LU1629891620.HKD","LU2106854487.HKD","LU1429558221.USD","LU1880398554.USD","LU0985320562.USD"],"gpt_icon":1},{"id":"2517159620","title":"Sophia Genetics price target lowered to $5 from $6 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2517159620","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517159620?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:16","pubTimestamp":1741263379,"startTime":"0","endTime":"0","summary":"BTIG lowered the firm’s price target on Sophia Genetics (SOPH) to $5 from $6 and keeps a Buy rating on the shares. The company turned in a relative...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sophia-genetics-price-target-lowered-to-5-from-6-at-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sophia-genetics-price-target-lowered-to-5-from-6-at-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","SOPH","BK4539"],"gpt_icon":0},{"id":"2517784990","title":"SOPHiA GENETICS Full Year 2024 Earnings: In Line With Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2517784990","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517784990?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 19:08","pubTimestamp":1741172923,"startTime":"0","endTime":"0","summary":"NasdaqGS:SOPH Earnings and Revenue Growth March 5th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue was in line with analyst estimates. Earnings per share  was also in line with analyst expectations.Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US.The company's shares are down 17% from a week ago.Don't forget that there may still be risks. For instance, we've identified   2 warning signs for SOPHiA GENETICS  that you should be aware of.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sophia-genetics-full-2024-earnings-110843992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SOPH"],"gpt_icon":0},{"id":"2517966269","title":"Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Highlights: Record Customer Growth Amidst ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2517966269","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517966269?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 15:04","pubTimestamp":1741158256,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Sophia Genetics SA  signed a record 92 new core genomic customers in 2024, including 31 in Q4, indicating strong market demand.The company achieved a 13% year-over-year growth in clinical analysis volume, excluding COVID-related impacts.The launch of new applications, MSK Access and MSK Impact, has been well-received, with 34 customers adopting MSK Access across 20 countries.A:  The company signed a record number of new customers in 2024, which should lead to increased volumes as implementations progress. ASPs were impacted by the end of sponsor testing in 2024, but new products like MSK Access and Impact, which have higher ASPs, are expected to contribute positively. The growth in 2025 is expected to be more volume-driven, with ASPs potentially increasing as new products become a larger part of the mix.A:  MSK Access and MSK Impact have shown strong uptake, with 34 customers for MSK Acc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sophia-genetics-sa-soph-q4-070416074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SOPH"],"gpt_icon":0},{"id":"2516605952","title":"Sophia Genetics SA reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516605952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516605952?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 23:54","pubTimestamp":1741103676,"startTime":"0","endTime":"0","summary":"Sophia Genetics SA reports results for the quarter ended December 31 - Earnings SummarySophia Genetics SA SOPH.OQ reported a quarterly adjusted loss of 23 cents per share for the quarter ended Decembe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL5N3PN1ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOPH"],"gpt_icon":0},{"id":"2516773916","title":"SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2516773916","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516773916?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:55","pubTimestamp":1741092902,"startTime":"0","endTime":"0","summary":"SOPHiA GENETICS SA  came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.17%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced a loss of $0.28, delivering a surprise of -16.67%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.SOPHiA GENETICS , which belongs to the Zacks Medical Info Systems industry, posted revenues of $17.73 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.36%. This compares to year-ago revenues of $17.05 million. The company has topped consensus revenue estimates just once over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the perfo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sophia-genetics-sa-soph-reports-125502436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SOPH"],"gpt_icon":0},{"id":"2516186678","title":"SOPHiA Genetics Reports Fourth Quarter and Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516186678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516186678?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:19","pubTimestamp":1741090774,"startTime":"0","endTime":"0","summary":"March 4 (Reuters) - Sophia Genetics SA <90B.F>::*SOPHIA GENETICS SA - 2025 REVENUE GUIDANCE $72 MILLION TO $76 MILLION*SOPHIA GENETICS SA - Q4 REVENUE $17.7 MILLION, UP 4% YEAR-OVER-YEAR*SOPHIA GENETI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nRSDbdTMgS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SOPH","BK4167"],"gpt_icon":0},{"id":"2516879620","title":"Sophia Genetics Q4 EPS $(0.23) Misses $(0.22) Estimate, Sales $17.73M Beat $17.72M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2516879620","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516879620?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:47","pubTimestamp":1741088832,"startTime":"0","endTime":"0","summary":"Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 37.84 percent increase over losses of $(0.37) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44104152/sophia-genetics-q4-eps-0-23-misses-0-22-estimate-sales-17-73m-beat-17-72m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Sophia Genetics Q4 EPS $(0.23) Misses $(0.22) Estimate, Sales $17.73M Beat $17.72M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOPH"],"gpt_icon":0},{"id":"2516627216","title":"Press Release: SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516627216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516627216?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:45","pubTimestamp":1741088700,"startTime":"0","endTime":"0","summary":"BOSTON and ROLLE, Switzerland, March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS , a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024.-- Revenue was $17.7 million, up 4% year-over-year or 6% on a constant. -- Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis,compared to 69.8% and 73.4% in the prior year period, respectively. -- Operating loss was $17.4 million on a reported basis and $10.2 million on. -- Gross margin was 67.4% on a reported basis and 72.8% on an adjusted basis,compared to 68.8% and 72.2% in the prior year period, respectively. an adjusted basis, representing year-over-year improvements of 11% and. -- Performed a record 352,000 analyses in FY 2024, representing 11%. year-over-year volume growth, or 13% when excluding COVID-related volumes. -- Reached 472 core genomics customers as of December 31, 2024, who use. SOPHiA DDM regularly to anal","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4232","TM","BK4099","BK4555","BK4022","BK4588","SOPH","R","BK4539","BK4604","BK4167","BK4585"],"gpt_icon":0},{"id":"2516687855","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687855?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 19:00","pubTimestamp":1740999600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·AG Mtge Invst Trst                              4Q       .20   6:30 AM. ·BRC Inc Class A                                 4Q      (.01)      AMC. ·Burford Capital Ltd                              4Q       .54   7:00 AM. ·Crawford & Co                                  4Q       .23   4:15 PM. ·Dave Inc. Class A                               4Q       .42       AMC. ·Heidrick & Struggles                            4Q       .63   4:01 PM. ·Hut 8 Corp.                                      4Q       .04   6:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTRE","NESR","DAVE","ESPR","RIGL","SQM","NPCE","RPTX","MRSN","PMTS","AZO","SCM","BRCC","GTLB","DSP","BWEN","SNDX","NVRO","SPHR","ANF","PLUG","BUR","INO","MITT","CRC","SOPH","YMAB","BMEA","CLRB","EOSE","JRVR","EC","FLUT","HUT","CRCT","CRDO","FATE","OCUL","OKTA","RPAY","EVGO","NOMD","OOMA","STIM","CTOS","TKNO","EBS","BLFS","CMRX","WVE"],"gpt_icon":0},{"id":"2514223833","title":"Sophia Genetics SA  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514223833","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514223833?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:54","pubTimestamp":1740750847,"startTime":"0","endTime":"0","summary":"Sophia Genetics SA  expected to post a loss of22cents a share - Earnings Preview Sophia Genetics SA SOPH.OQ, SOPH.O is expected to show a rise in quarterly revenue when it reports  results on March 4 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL5N3PJ1FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOPH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sophiagenetics.com","stockEarnings":[{"period":"1week","weight":0.089},{"period":"1month","weight":-0.0192},{"period":"3month","weight":-0.2933},{"period":"6month","weight":-0.15},{"period":"1year","weight":-0.3953},{"period":"ytd","weight":-0.0033}],"compareEarnings":[{"period":"1week","weight":0.0186},{"period":"1month","weight":-0.0673},{"period":"3month","weight":-0.1219},{"period":"6month","weight":-0.0753},{"period":"1year","weight":0.0589},{"period":"ytd","weight":-0.0864}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.100171},{"month":2,"riseRate":0.75,"avgChangeRate":0.024645},{"month":3,"riseRate":0.25,"avgChangeRate":0.101519},{"month":4,"riseRate":0.25,"avgChangeRate":-0.059541},{"month":5,"riseRate":0,"avgChangeRate":-0.138634},{"month":6,"riseRate":0,"avgChangeRate":-0.08282},{"month":7,"riseRate":0,"avgChangeRate":-0.079349},{"month":8,"riseRate":0.25,"avgChangeRate":-0.067072},{"month":9,"riseRate":0.25,"avgChangeRate":-0.080089},{"month":10,"riseRate":0.25,"avgChangeRate":0.019174},{"month":11,"riseRate":0.5,"avgChangeRate":0.019286},{"month":12,"riseRate":0.5,"avgChangeRate":-0.006927}],"exchange":"NASDAQ","name":"SOPHiA GENETICS SA","nameEN":"SOPHiA GENETICS SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SOPHiA GENETICS SA(SOPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SOPHiA GENETICS SA(SOPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SOPHiA GENETICS SA,SOPH,SOPHiA GENETICS SA股票,SOPHiA GENETICS SA股票老虎,SOPHiA GENETICS SA股票老虎国际,SOPHiA GENETICS SA行情,SOPHiA GENETICS SA股票行情,SOPHiA GENETICS SA股价,SOPHiA GENETICS SA股市,SOPHiA GENETICS SA股票价格,SOPHiA GENETICS SA股票交易,SOPHiA GENETICS SA股票购买,SOPHiA GENETICS SA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SOPHiA GENETICS SA(SOPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SOPHiA GENETICS SA(SOPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction